MorphoSys AG (WBO:MOR)
€ 67.6 0.8 (1.2%) Market Cap: 2.52 Bil Enterprise Value: 2.48 Bil PE Ratio: 0 PB Ratio: 52.00 GF Score: 59/100

Morphosys AG To Discuss Results From The Primary Analysis Of The Ongoing Single-Arm Phase 2 Clinical Trial L-MIND Conference Call Transcript

May 20, 2019 / 12:00PM GMT
Release Date Price: €93.5 (-0.11%)
Operator

Ladies and gentlemen, welcome to the MorphoSys conference call. (Operator Instructions) The conference is being recorded. (Operator Instructions) Now I would like to turn the call over to Sarah Fakih. Please go ahead.

Sarah Fakih
MorphoSys AG - VP & Head of Corporate Communications and IR

Good afternoon, good morning, and welcome to our Q&A call following the publications of the primary L-MIND analysis data on Thursday last week.

My name is Sarah Fakih and I'm the Head of Corporate Communications and Investor Relations at MorphoSys. With me on the call today are Simon Moroney, our Chief Executive Officer; Jens Holstein, our Chief Financial Officer; and Malte Peters, our Chief Development Officer.

Before we start, I would like to remind you that during this conference call, we will discuss certain forward-looking statements concerning the development of MorphoSys core technologies, the progress of its current research and development programs and the initiation of additional programs. Should actual results differ from the company's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot